Risk factors and treatment of relapses in autoimmune pancreatitis: Rituximab is safe and effective
Heithem Soliman(Hôpital Louis-Mourier), Vinciane Rebours(Hôpital Beaujon), Marie‐Pierre Vullierme, Philippe Lévy(Hôpital Beaujon), Philippe Ruszniewski(Institut de Recherche contre les Cancers de l’Appareil Digestif), Frédérique Maire(Université Paris Cité), Olivia Hentic(Université Paris Cité)
Cited by 54
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Gastroenteropancreatic neuroendocrine tumours
|The Lancet Oncology|2008|1.8k
Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids
|Annals of Oncology|2015|698
Determinant-Based Classification of Acute Pancreatitis Severity
|Annals of Surgery|2012|516